ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision

Maciej J. Zamek-Gliszczynski, Xiaoyan Chu, Jack A. Cook, Joseph M. Custodio, Aleksandra Galetin, Kathleen M. Giacomini, Caroline A. Lee, Mary F. Paine, Adrian S. Ray, Joseph A. Ware, Matthias B. Wittwer, Lei Zhang

Research output: Contribution to journalArticlepeer-review

442 Downloads (Pure)

Abstract

Metformin drug-drug interaction (DDI) studies are conducted during development of drugs that inhibit organic cation transporters and/or multidrug and toxin extrusion proteins (OCTs/MATEs). Monitoring solely changes in systemic exposure, the typical DDI study endpoint appears inadequate for metformin, which is metabolically stable, has poor passive membrane permeability, and undergoes transporter-mediated tissue distribution and clearance. Evaluation of renal clearance, antihyperglycemic effects, and potentially lactate as an exploratory safety marker, can support rational metformin dose adjustment. The proposed DDI study design aims to adequately inform metformin dosing during comedication.

Original languageEnglish
JournalClinical Pharmacology and Therapeutics
Early online date15 May 2018
DOIs
Publication statusPublished - 2018

Fingerprint

Dive into the research topics of 'ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision'. Together they form a unique fingerprint.

Cite this